## Marcella Nebbioso

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5034720/publications.pdf

Version: 2024-02-01

88 papers 1,409 citations

331259 21 h-index 433756 31 g-index

94 all docs 94 docs citations

times ranked

94

1815 citing authors

#	Article	IF	CITATIONS
1	Curcumin: Therapeutical Potential in Ophthalmology. Planta Medica, 2014, 80, 249-254.	0.7	90
2	SIRT1 silencing confers neuroprotection through IGFâ€1 pathway activation. Journal of Cellular Physiology, 2013, 228, 1754-1761.	2.0	50
3	Cell surgery and growth factors in dry age-related macular degeneration: visual prognosis and morphological study. Oncotarget, 2016, 7, 46913-46923.	0.8	47
4	Quality of life and neuropsychiatric disorders in patients with Graves' Orbitopathy: Current concepts. Autoimmunity Reviews, 2018, 17, 639-643.	2.5	44
5	Oxidative Stress in Preretinopathic Diabetes Subjects and Antioxidants. Diabetes Technology and Therapeutics, 2012, 14, 257-263.	2.4	42
6	Therapeutic potential of curcumin in major retinal pathologies. International Ophthalmology, 2019, 39, 725-734.	0.6	41
7	Scotopic Microperimetry in the Early Diagnosis of Age-Related Macular Degeneration: Preliminary Study. BioMed Research International, 2014, 2014, 1-7.	0.9	37
8	Modulatory effects of 1,25-dihydroxyvitamin D3 on eye disorders: A critical review. Critical Reviews in Food Science and Nutrition, 2017, 57, 559-565.	5.4	35
9	Therapeutic Approaches with Intravitreal Injections in Geographic Atrophy Secondary to Age-Related Macular Degeneration: Current Drugs and Potential Molecules. International Journal of Molecular Sciences, 2019, 20, 1693.	1.8	35
10	Preliminary Study on Electrophysiological Changes After Cellular Autograft in Age-Related Macular Degeneration. Medicine (United States), 2014, 93, e355.	0.4	34
11	Role of Protease-Inhibitors in Ocular Diseases. Molecules, 2014, 19, 20557-20569.	1.7	33
12	Lipoic acid in animal models and clinical use in diabetic retinopathy. Expert Opinion on Pharmacotherapy, 2013, 14, 1829-1838.	0.9	31
13	Analysis of the Pathogenic Factors and Management of Dry Eye in Ocular Surface Disorders. International Journal of Molecular Sciences, 2017, 18, 1764.	1.8	30
14	Pathogenesis of Vernal Keratoconjunctivitis and Associated Factors. Seminars in Ophthalmology, 2015, 30, 340-344.	0.8	29
15	Role of Dopaminergic Receptors in Glaucomatous Disease Modulation. BioMed Research International, 2013, 2013, 1-5.	0.9	27
16	Highâ€mobility group boxâ€1 ( <scp>HMGB</scp> â€1) and serum soluble receptor for advanced glycation end products ( <scp>sRAGE</scp> ) in children affected by vernal keratoconjunctivitis. Pediatric Allergy and Immunology, 2014, 25, 57-63.	1.1	26
17	Psychophysical and Electrophysiological Testing in Ocular Hypertension. Optometry and Vision Science, 2011, 88, E928-E939.	0.6	24
18	Management of anterior chamber dislocation of a dexamethasone intravitreal implant: a case report. Journal of Medical Case Reports, 2016, 10, 282.	0.4	24

#	Article	IF	CITATIONS
19	Monoamine oxidase enzymes and oxidative stress in the rat optic nerve: ageâ€related changes. International Journal of Experimental Pathology, 2012, 93, 401-405.	0.6	23
20	Comparison of Short-Term Choroidal Thickness and Retinal Morphological Changes after Intravitreal Anti-VEGF Therapy with Ranibizumab or Aflibercept in Treatment-Naive Eyes. Current Eye Research, 2018, 43, 391-396.	0.7	23
21	Early Detection of Macular Changes With Multifocal ERG in Patients on Antimalarial Drug Therapy. Journal of Ocular Pharmacology and Therapeutics, 2009, 25, 249-258.	0.6	22
22	Vernal keratoconjunctivitis treated with omalizumab: A case series. Pediatric Allergy and Immunology, 2017, 28, 503-505.	1.1	22
23	Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary <em>In Vivo</em> Report. Journal of Visualized Experiments, 2018, , .	0.2	22
24	Trabecular Meshwork in Normal and Pathological Eyes. Ultrastructural Pathology, 2012, 36, 102-107.	0.4	20
25	New trends in visual rehabilitation with MP-1 microperimeter biofeedback: optic neural dysfunction. Functional Neurology, 2013, 28, 285-91.	1.3	20
26	Retina in rheumatic diseases: Standard full field and multifocal electroretinography in hydroxychloroquine retinal dysfunction. Australasian journal of optometry, The, 2011, 94, 276-283.	0.6	18
27	Visual rehabilitation in patients with myopic maculopathy: our experience. Canadian Journal of Ophthalmology, 2013, 48, 438-442.	0.4	17
28	Diabetic retinopathy, oxidative stress, and sirtuins: an in depth look in enzymatic patterns and new therapeutic horizons. Survey of Ophthalmology, 2022, 67, 168-183.	1.7	17
29	Mechanisms of ocular neuroprotection by antioxidant molecules in animal models. Journal of Biological Regulators and Homeostatic Agents, 2013, 27, 197-209.	0.7	17
30	Palmitoylethanolamide Effects on Intraocular Pressure After Nd:YAG Laser Iridotomy: An Experimental Clinical Study. Journal of Ocular Pharmacology and Therapeutics, 2011, 27, 629-635.	0.6	16
31	Immunogenetic investigation in vernal keratoconjunctivitis. Pediatric Allergy and Immunology, 2014, 25, 508-510.	1.1	16
32	Vernal Keratoconjunctivitis and immuneâ€mediated diseases: One unique way to symptom control?. Pediatric Allergy and Immunology, 2015, 26, 289-291.	1.1	16
33	Investigational drugs in dry eye disease. Expert Opinion on Investigational Drugs, 2016, 25, 1437-1446.	1.9	16
34	The Complex Relationship between Diabetic Retinopathy and High-Mobility Group Box: A Review of Molecular Pathways and Therapeutic Strategies. Antioxidants, 2020, 9, 666.	2.2	16
35	The role of inflammation in diabetic retinopathy: a review. European Review for Medical and Pharmacological Sciences, 2020, 24, 10319-10329.	0.5	16
36	Role of the Dopaminergic System in the Development of Myopia in Children and Adolescents. Journal of Child Neurology, 2014, 29, 1739-1746.	0.7	15

#	Article	IF	Citations
37	Stem Cell Surgery and Growth Factors in Retinitis Pigmentosa Patients: Pilot Study after Literature Review. Biomedicines, 2019, 7, 94.	1.4	15
38	Hypobaric Hypoxia: Effects on Intraocular Pressure and Corneal Thickness. Scientific World Journal, The, 2014, 2014, 1-5.	0.8	14
39	Genetic Analysis for Two Italian Siblings with Usher Syndrome and Schizophrenia. Case Reports in Ophthalmological Medicine, 2012, 2012, 1-6.	0.3	13
40	Microincision Vitrectomy Surgery in Vitreomacular Traction Syndrome of Retinitis Pigmentosa Patients. BioMed Research International, 2014, 2014, 1-7.	0.9	13
41	Multifocal and pattern-reversal visual evoked potentials vs. automated perimetry frequency-doubling technology matrix in optic neuritis. Indian Journal of Ophthalmology, 2013, 61, 59.	0.5	12
42	Assessment of Corneal Alterations by Confocal Microscopy in Vernal Keratoconjunctivitis. Seminars in Ophthalmology, 2015, 30, 40-43.	0.8	12
43	Antiâ€'inflammatory role of curcumin in retinal disorders (Review). Experimental and Therapeutic Medicine, 2021, 22, 790.	0.8	12
44	Recent Advances and Disputes About Curcumin in Retinal Diseases. Clinical Ophthalmology, 2021, Volume 15, 2553-2571.	0.9	12
45	Retinal and Orbital Venous Occlusions Treated with Enoxaparin. Journal of Ocular Pharmacology and Therapeutics, 2008, 24, 421-426.	0.6	11
46	Cataract Surgery Complications. Drugs in R and D, 2011, 11, 303-307.	1.1	11
47	New insight into visual function with aspherical intraocular lenses (IOLs): Tecnis ZCB00 and Acrysof SN60WF. International Ophthalmology, 2011, 31, 417-419.	0.6	11
48	latrogenic dry eye disease: An eledoisin/carnitine and osmolyte drops study. Biomedicine and Pharmacotherapy, 2013, 67, 659-663.	2.5	11
49	Tear Ferning Test and Pathological Effects on Ocular Surface before and after Topical Cyclosporine in Vernal Keratoconjunctivitis Patients. Journal of Ophthalmology, 2018, 2018, 1-11.	0.6	11
50	<p>Eye drop emulsion containing 0.1% cyclosporin (1 mg/mL) for the treatment of severe vernal keratoconjunctivitis: an evidence-based review and place in therapy</p> . Clinical Ophthalmology, 2019, Volume 13, 1147-1155.	0.9	11
51	Evaluation of <scp>IL</scp> 8 pathway on the ocular surface: new insights in patients with ocular mucous membrane pemphigoid. Acta Ophthalmologica, 2020, 98, e173-e177.	0.6	11
52	Arteritic anterior ischemic optic neuropathy treated with intravenous prostaglandin Eland steroids. International Journal of Angiology, 2010, 19, e113-e115.	0.2	10
53	Vitamin D levels in children affected by vernal keratoconjunctivitis. Current Medical Research and Opinion, 2017, 33, 269-274.	0.9	10
54	Treatment of glaucomatous patients by means of food supplement to reduce the ocular discomfort: a double blind randomized trial. European Review for Medical and Pharmacological Sciences, 2013, 17, 1117-22.	0.5	10

#	Article	IF	Citations
55	Antioxidant and Biological Properties of Mesenchymal Cells Used for Therapy in Retinitis Pigmentosa. Antioxidants, 2020, 9, 983.	2.2	9
56	Fixed topical combinations in glaucomatous patients and ocular discomfort. Expert Opinion on Pharmacotherapy, 2012, 13, 1829-1835.	0.9	8
57	Macular hole in retinitis pigmentosa patients: microincision vitrectomy with polydimethylsiloxane as possible treatment. Eye, 2015, 29, 699-702.	1.1	8
58	<p>Neurofibromatosis Type 1: Ocular Electrophysiological and Perimetric Anomalies</p> . Eye and Brain, 2020, Volume 12, 119-127.	3.8	8
59	Visual Recovery after Primary Retinal Detachment Surgery: Biofeedback Rehabilitative Strategy. Journal of Ophthalmology, 2016, 2016, 1-5.	0.6	7
60	Is oxidative stress involved in vernal keratoconjunctivitis? Results from a pilot study in children. Pediatric Allergy and Immunology, 2020, 31, 52-56.	1.1	7
61	Intracameral lidocaine as supplement to classic topical anesthesia for relieving ocular pain in cataract surgery. International Journal of Ophthalmology, 2018, 11, 1932-1935.	0.5	7
62	Non-arteritic Posterior Ischaemic Optic Neuropathy Treated with Intravenous Prostaglandin E1 and Oral Corticosteroids. Neuro-Ophthalmology, 2011, 35, 81-84.	0.4	6
63	Mesenchymal stem and non-stem cell surgery, rescue, and regeneration in glaucomatous optic neuropathy. Stem Cell Research and Therapy, 2021, 12, 275.	2.4	6
64	OCULAR ISCHEMIA IN HIGH MYOPIA TREATED WITH INTRAVENOUS PROSTAGLANDIN E1. Retinal Cases and Brief Reports, 2009, 3, 379-382.	0.3	5
65	Degenerative effects in rat eyes after experimental ocular hypertension. European Journal of Histochemistry, 2012, 56, 42.	0.6	5
66	Cystic Fibrosis and New Trends by Ophthalmological Evaluation: A Pilot Study. BioMed Research International, 2014, 2014, 1-5.	0.9	5
67	Three episodes of non-arteritic posterior ischemic optic neuropathy in the same patient treated with intravenous prostaglandin E1. Drug Discoveries and Therapeutics, 2016, 10, 177-180.	0.6	5
68	Ten-Year Outcomes of Intravitreal Bevacizumab for Myopic Choroidal Neovascularization: Analysis of Prognostic Factors. Pharmaceuticals, 2021, 14, 1042.	1.7	5
69	The effect of latanoprost and influence of changes in body position on patients with glaucoma and ocular hypertension. European Review for Medical and Pharmacological Sciences, 2012, 16, 1723-8.	0.5	5
70	Vernal keratoconjunctivitis: state of art and update on treatment. Acta Biomedica, 2021, 92, e2021517.	0.2	5
71	Biomolecular Modulation of Neurodegenerative Events during Ageing. Oxidative Medicine and Cellular Longevity, 2015, 2015, 1-10.	1.9	4
72	Vascular Endothelial Growth Factor (VEGF) Serological and Lacrimal Signaling in Patients Affected by Vernal Keratoconjunctivitis (VKC). Journal of Ophthalmology, 2018, 2018, 1-6.	0.6	4

#	Article	IF	CITATIONS
73	High myopic patients with and without foveoschisis: morphological and functional characteristics. Documenta Ophthalmologica, 2020, 141, 227-236.	1.0	4
74	Forskolin and rutin prevent intraocular pressure spikes after Nd:YAG laser iridotomy. Panminerva Medica, 2012, 54, 77-82.	0.2	4
75	Current and emerging treatment options for vernal keratoconjunctivitis. Expert Opinion on Orphan Drugs, 2017, 5, 343-353.	0.5	3
76	Visual field improvement in non-arteritic posterior ischemic optic neuropathy in a patient treated with intravenous prostaglandin E1 and steroids. Drug Discoveries and Therapeutics, 2017, 11, 226-229.	0.6	3
77	Complement Mediators in Development to Treat Age-Related Macular Degeneration. Drugs and Aging, 2022, 39, 107.	1.3	3
78	Visual improvement in a patient with paracentral acute middle maculopathy treated with prostaglandin E1. Drug Discoveries and Therapeutics, 2020, 14, 98-99.	0.6	2
79	X-linked dominant RPGR gene mutation in a familial Coats angiomatosis. BMC Ophthalmology, 2021, 21, 37.	0.6	2
80	Impact of screen exposure on pediatric vernal Keratoconjunctivitis: a survey during the COVID-19 pandemic in Italy. Italian Journal of Pediatrics, 2022, 48, 74.	1.0	2
81	AN ISCHEMIC DIABETIC EYE TREATED WITH INTRAVENOUS PROSTAGLANDIN E1. Retinal Cases and Brief Reports, 2014, 8, 21-23.	0.3	1
82	Surgical management by means of electroretinographic examination during extracorporeal circulation. Annali Italiani Di Chirurgia, 2012, 83, 523-8.	0.1	1
83	Oxidative stress in the closed-eyelid test: management of glaucoma. European Review for Medical and Pharmacological Sciences, 2012, 16, 1453-7.	0.5	1
84	Utility of retinal thickness analyzer in early diagnosis of glaucomatous damage. In Vivo, 2015, 29, 385-90.	0.6	1
85	Post-operative hospitalization in retinal detachment correlation to recurrences. Annali Dell'Istituto Superiore Di Sanita, 2013, 49, 336-9.	0.2	1
86	Electrophysiological Study of Visual Pathways in Nevoid Basal Cell Carcinoma Syndrome Patients. Eye and Brain, 2021, Volume 13, 71-78.	3.8	0
87	Multidisciplinary Study Based on Clinical, Electrophysiological and Psycological Evaluations Combined with Advanced Neuroimaging in Gaucher Disease Patients. Blood, 2019, 134, 2185-2185.	0.6	0
88	Multi-Parameter Neurological Study Based on Combined Conventional and Functional Assessments in Gaucher Disease Patients (SENOPRO_GAUCHER Study). Blood, 2020, 136, 12-12.	0.6	0